A new onceaday pill may help patients with a hardtotreat form of   live longer and healthier lives and free them from unpleasant drug infusions at the same time doctors reported Saturday Some of the patients given the pill called Imbruvica are still alive against the odds the researchers told a meeting of the American Society of Clinical Oncology Its a rare advance in the world of cancer treatment which usually moves forward with steady but slow progress The numbers were remarkable said ASCO president Dr Cliff Hudis who was not involved in the study There was a  percent decrease in the risk of dying with the new pill People who got the monoclonal which is given as a regular infusion lived an average of  months In comparison  percent of those who took the pill lived  months or longer and many are still alive The pill reduced the risk of death by  percent Dr John Byrd of Ohio State University Medical Center told a news conference Byrd and colleagues tested Imbruvica in  patients with chronic lymphocytic leukemia which can be a slowgrowing cancer But not always The patients in this trial didnt have much hope  their cancer had come back despite several previous rounds of treatment They were on average  years old Half got Imbruvica and half got the best standard treatment an infused drug called ofatumumab or Arzerra Arzerra itself is a targeted therapy  a socalled monoclonal antibody which is an engineered immune system molecule designed to target tumor cells Imbruvica known generically as ibrutinib is a pill that targets a certain cancercausing mutation At  months the overall survival rate was  percent in the ibrutinib group and  percent in the ofatumumab group Byrds team wrote in a brief report in the New England Journal of Medicine ASCO chose to highlight the findings because Imbruvica is already approved by the Food and Drug Administration for use against a different blood cancer called mantle cell lymphoma as well as for chronic lymphocytic leukemia That means cancer specialists can start offering it to their patients right away CLL is the  in adults and is diagnosed in more than  people a year killing  Standard treatment include intensive chemotherapy But thats something older patients cannot always tolerate If they can take a pill once a day instead of getting an IV and  live longer for me this is a huge step forward says Dr Richard Schilsky chief medical officer for ASCO This is going to change the way we treat CLL said Lee Greenberger chief scientific officer for the Leukemia  Lymphoma Society 